DDInter1024 DDInter1940
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Lapatinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Lapatinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)
Lapatinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Lapatinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Lapatinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Lapatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)